Welcome
Support Centre
09 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised Phase I/II - Study with Ghrelin versus Placebo for patients with cancer-related Anorexia/Cachexia
ISRCTN ISRCTN26185223
ClinicalTrials.gov identifier
Public title Randomised Phase I/II - Study with Ghrelin versus Placebo for patients with cancer-related Anorexia/Cachexia
Scientific title
Acronym Ghrelin
Serial number at source SG 242/03
Study hypothesis Ghrelin is a safe new treatment option in patients with advanced cancer and involuntary loss of weight and appetite.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Switzerland
Disease/condition/study domain Cancer-related anorexia/cachexia
Participants - inclusion criteria Patients with any type of advanced, incurable cancer, not requiring new or not being on antineoplastic treatment during the study period, with weight loss (>2% 2 months or >5% 6 months) and anorexia (VAS >3) will be eligible.
Participants - exclusion criteria Severe structural barriers in the upper gastrointestinal tract, bowel obstruction.
Anticipated start date 01/03/2004
Anticipated end date 01/09/2005
Status of trial Completed
Patient information material
Target number of participants 20
Interventions Ghrelin intravenous versus placebo.
Primary outcome measure(s) 1. Safety of parenteral Ghrelin administered in patients with advanced cancer suffering from the anorexia/cachexia syndrome
2. Qualitative and quantitative toxicities
Secondary outcome measure(s) Symptomatic effect of parenteral Ghrelin on appetite, other anorexia/cachexia related symptoms, and health-related quality-of-life (HRQOL) in patients with advanced cancer suffering from the anorexia/cachexia syndrome.
Effect of parenteral Ghrelin on nutritional intake and food preferences.
Sources of funding Pilot Grant Swiss Institute for Applied Cancer REsearch; REsearch Grant OncoSuisse; Cancer League Eastern Switzerland; ALTANA Prize; Gastrotech DK
Trial website
Publications
Contact name Dr  Florian  Strasser
  Address Oncology and Palliative Medicine
Section Oncology/Haematology
Dept. Internal Medicine
Cantonal Hospital
  City/town St.Gallen
  Zip/Postcode 9007
  Country Switzerland
Sponsor Cantonal Hospital (Switzerland)
  Address Oncology/Haematology Dept
Internal Medicine
Cantonal Hospital
Rorschacherstrasse
  City/town St.Gallen
  Zip/Postcode 9007
  Country Switzerland
Date applied 08/07/2005
Last edited 06/08/2007
Date ISRCTN assigned 12/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central